Ravneesh Sachdev is Senior Vice President and Head of Business Development at Acceleron Pharma based in Cambridge, MA. Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics arising from the company’s leadership in TGF-beta superfamily biology and protein engineering that engage the body’s ability to regulate cellular growth and repair to treat serious and rare hematologic and pulmonary diseases. Under a global collaboration with Bristol Myers Squibb, Acceleron’s first commercial product, REBLOZYL® (luspatercept-aamt), became the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders.
Sachdev leads a team to evaluate and transact on partnerships in order to inorganically grow Acceleron’s business. Over the past 15+ years of his business development career, he has contributed to, as well as led, the execution of more than 25 partnerships during his tenure at several other companies, namely Pfizer, Onyx Pharmaceuticals (now part of Amgen), UCB Pharma, Acorda Therapeutics, Bioverativ (now part of Sanofi), and Sage Therapeutics.
Sachdev earned his bachelor’s degree in Molecular Neuroscience from Claremont McKenna College, his Master of Business and Science degree from Keck Graduate Institute, and his MBA in Healthcare Leadership from Yale University School of Management.